Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Impedimed Limited ( (AU:IPD) ) has provided an announcement.
Impedimed Limited has applied to the ASX for quotation of 870,255 new fully paid ordinary shares, which were issued to an executive as part of their base remuneration for the quarter ended 31 December 2025 under the company’s Executive Share Plan. The move modestly increases the company’s share count and reflects Impedimed’s continued use of equity-based compensation to remunerate senior management, aligning executive interests with shareholders while managing cash outflows.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited is an Australian-listed medical technology company (ASX: IPD) focused on developing and commercialising bioimpedance-based devices and solutions, primarily used for the assessment and monitoring of conditions such as lymphoedema and fluid status in clinical settings. The company targets healthcare providers and hospital markets seeking non-invasive diagnostic and monitoring tools that support improved patient management and outcomes.
Average Trading Volume: 1,536,061
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$71.31M
See more data about IPD stock on TipRanks’ Stock Analysis page.